Germany · Delayed Price · Currency is EUR Wacker Chemie AG Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw sales decline 5% year-over-year to EUR 1.41 billion, but EBITDA surged 45% to EUR 173 million, driven by cost savings and customer order pull-forwards. Full-year EBITDA guidance is unchanged, but outlook remains uncertain due to geopolitical and market risks.
Fiscal Year 2025
-
Sales and EBITDA met revised guidance but were impacted by EUR 705 million in restructuring and impairments, resulting in a net loss and no dividend. The PACE program targets EUR 300 million in annual savings, with 1,500 job cuts, while 2026 guidance anticipates modest growth and improved cash flow.
-
Q3 2025 saw sales and EBITDA decline amid weak demand, price pressure, and regulatory uncertainty, with all segments affected. Full-year guidance was lowered, and a comprehensive cost-saving program is underway to restore competitiveness and profitability.
-
Q2 2025 saw weak demand, intense competition, and currency headwinds, leading to a lowered full-year outlook. Sales and EBITDA declined year-over-year, with segment performance mixed and cost, cash, and growth initiatives prioritized. Net debt rose, and market conditions remain challenging.
-
Q1 2025 saw sales of €1.48 billion, down 1% year-over-year, with EBITDA at €127 million due to weak solar and construction demand. Specialty silicones and biopharma showed strength, while trade and tariff uncertainties continue to weigh on the outlook.
Fiscal Year 2024
-
2024 saw lower group sales and EBITDA due to polysilicon weakness, but specialty silicones and biosolutions delivered strong growth. 2025 guidance anticipates higher sales and EBITDA, with continued focus on specialty growth, efficiency, and sustainability.
-
Q3 2024 sales fell 6% year-over-year to €1.4 billion, but specialty chemicals and biosolutions delivered strong growth and improved margins. Polysilicon sales declined due to solar market uncertainty, while full-year EBITDA is expected in the upper half of €600–800 million.
-
Q2 2024 saw strong Chemicals and Polysilicon results, with group sales at EUR 1.5 billion and EBITDA of EUR 160 million. Full-year EBITDA is expected in the upper half of guidance, with H2 performance to improve, especially in Biosolutions and Polysilicon.